133 related articles for article (PubMed ID: 34003574)
1. Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study.
Di Giannatale A; Di Paolo PL; Curione D; Lenkowicz J; Napolitano A; Secinaro A; Tomà P; Locatelli F; Castellano A; Boldrini L
Pediatr Blood Cancer; 2021 Sep; 68(9):e29110. PubMed ID: 34003574
[TBL] [Abstract][Full Text] [Related]
2. Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification.
Wu H; Wu C; Zheng H; Wang L; Guan W; Duan S; Wang D
Eur Radiol; 2021 May; 31(5):3080-3089. PubMed ID: 33118047
[TBL] [Abstract][Full Text] [Related]
3. CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.
Tan E; Merchant K; Kn BP; Cs A; Zhao JJ; Saffari SE; Tan PH; Tang PH
Childs Nerv Syst; 2022 Aug; 38(8):1487-1495. PubMed ID: 35460355
[TBL] [Abstract][Full Text] [Related]
4. A Random Forest-based Classifier for MYCN Status Prediction in Neuroblastoma using CT Images.
Pereira T; Silva F; Claro P; Carvalho DC; Dias SC; Torrao H; Oliveira HP
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():3854-3857. PubMed ID: 36086471
[TBL] [Abstract][Full Text] [Related]
5. CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma.
Chen X; Wang H; Huang K; Liu H; Ding H; Zhang L; Zhang T; Yu W; He L
Front Oncol; 2021; 11():687884. PubMed ID: 34109133
[TBL] [Abstract][Full Text] [Related]
6. Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature.
Qian LD; Zhang SX; Li SQ; Feng LJ; Zhou ZA; Liu J; Zhang MY; Yang JG
Insights Imaging; 2023 Nov; 14(1):205. PubMed ID: 38001240
[TBL] [Abstract][Full Text] [Related]
7. Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas.
Ghosh A; Yekeler E; Teixeira SR; Dalal D; States L
Eur Radiol; 2023 Oct; 33(10):6726-6735. PubMed ID: 37178203
[TBL] [Abstract][Full Text] [Related]
8. Prediction of MYCN Gene Amplification in Pediatric Neuroblastomas: Development of a Deep Learning-Based Tool for Automatic Tumor Segmentation and Comparative Analysis of Computed Tomography-Based Radiomics Features Harmonization.
Yeow LY; Teh YX; Lu X; Srinivasa AC; Tan E; Tan TSE; Tang PH; Kn BP
J Comput Assist Tomogr; 2023 Sep-Oct 01; 47(5):786-795. PubMed ID: 37707410
[TBL] [Abstract][Full Text] [Related]
9.
Qian LD; Zhou ZA; Li SQ; Liu J; Zhang SX; Ren JL; Wang W; Yang J
Quant Imaging Med Surg; 2024 Apr; 14(4):3131-3145. PubMed ID: 38617169
[TBL] [Abstract][Full Text] [Related]
10. Whole-tumour apparent diffusion coefficient (ADC) histogram analysis to identify MYCN-amplification in neuroblastomas: preliminary results.
Ghosh A; Yekeler E; Dalal D; Holroyd A; States L
Eur Radiol; 2022 Dec; 32(12):8453-8462. PubMed ID: 35437614
[TBL] [Abstract][Full Text] [Related]
11. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
12. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
13. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
15. Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric Neuroblastoma
Qian L; Yang S; Zhang S; Qin H; Wang W; Kan Y; Liu L; Li J; Zhang H; Yang J
Front Med (Lausanne); 2022; 9():840777. PubMed ID: 35372427
[TBL] [Abstract][Full Text] [Related]
16. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
17. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
[TBL] [Abstract][Full Text] [Related]
18. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
[TBL] [Abstract][Full Text] [Related]
19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
20. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
